Randomized phase II study of everolimus (E), leuprolide plus letrozole (LL), and E plus LL (ELL) in patients (pts) with unresectable fibrolamellar carcinoma (FLC)

被引：2

作者：

Abou-Alfa, Ghassan K.

Mayer, Robert J.

Cosgrove, David

Capanu, Marinela

Choti, Michael A.

Atreya, Chloe Evelyn

Ang, Celina

Kelley, Robin Kate

Do, Richard Kinh Gian

Gordan, John Dozier

Zhu, Andrew X.

Ly, Michele

Nolan, Patrick

Lubin, Lakeisha

Harding, James J.

Saltz, Leonard

Venook, Alan P.

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[2] Weill Cornell Med Coll, New York, NY USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Sidney Kimmel Comp Canc Ctr, Baltimore, MD USA

[5] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA

[6] Univ Calif San Francisco, San Francisco, CA 94143 USA

[7] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

[8] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

来源：

关键词：

D O I：

10.1200/jco.2015.33.15_suppl.e15149

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

e15149

引用

页数：1